News|Articles|August 27, 2026
Five Key Posters From the 2026 SNO/ASCO CNS Metastases Conference
Author(s)Cancer Network Staff
Fact checked by: Tim Cortese, Russ Conroy
New CNS metastasis data link gabapentin to fewer brain mets, spotlight trial barriers, and show promise for intrathecal therapy and osimertinib.
Advertisement
Advertisement
The 2026 SNO/ASCO CNS Metastases Conference brought together a multidisciplinary audience of neuro-oncologists, radiation oncologists, neurosurgeons, medical oncologists, and translational researchers to address the growing burden of brain and leptomeningeal metastases across tumor types. The meeting highlighted basic and translational research into central nervous system (CNS) tropism and the metastatic microenvironment alongside clinical sessions on precision neurosurgery, modern radiotherapy techniques, and the integration of systemic and CNS-directed therapies.
Advertisement
Advertisement
